Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Authors
Keywords
-
Journal
LEUKEMIA
Volume 35, Issue 5, Pages 1229-1242
Publisher
Springer Science and Business Media LLC
Online
2021-04-08
DOI
10.1038/s41375-021-01238-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Donor Lymphocyte Infusion (DLI) in Post Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era
- (2020) Sarah Schmidt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α
- (2020) Raquel Alves et al. Journal of Translational Medicine
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
- (2020) Yazad D. Irani et al. BRITISH JOURNAL OF HAEMATOLOGY
- Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation
- (2020) Elisa Diral et al. BLOOD
- RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
- (2020) Shady Adnan Awad et al. LEUKEMIA
- NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
- (2019) Ming-Chin Chang et al. Frontiers in Immunology
- Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells
- (2019) Puneet Agarwal et al. Cell Stem Cell
- Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells
- (2019) Emilie Cayssials et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway
- (2019) Xiaoyan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
- (2019) Anna M. Paczulla et al. NATURE
- Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
- (2019) Anna Kreutzman et al. OncoImmunology
- Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial
- (2019) Fernanda S Seguro et al. BLOOD
- Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
- (2019) Lu Zhou et al. OncoTargets and Therapy
- A Phase 1 Trial of CNDO-109–Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia
- (2018) Todd A. Fehniger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation
- (2018) Yunxin Zeng et al. Clinical Laboratory
- Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
- (2018) Masaya Okada et al. Clinical Lymphoma Myeloma & Leukemia
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
- (2018) Oscar Brück et al. LEUKEMIA
- Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study
- (2018) Yuho Najima et al. LEUKEMIA RESEARCH
- Therapy-free remission in chronic myeloid leukemia: possible mechanism
- (2018) Robert Peter Gale et al. Expert Review of Hematology
- Allelic Polymorphisms of KIR s and HLA s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML
- (2018) Hiroshi Ureshino et al. Cancer Immunology Research
- Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia
- (2018) Sabrina Inselmann et al. CANCER RESEARCH
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells
- (2018) Walid Warda et al. CANCER RESEARCH
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
- (2017) Delphine Rea et al. HAEMATOLOGICA
- Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
- (2017) Hanna L. M. Rajala et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia
- (2017) Sieghart Sopper et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
- (2017) C Schütz et al. LEUKEMIA
- Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs)
- (2017) Djamel Aggoune et al. LEUKEMIA RESEARCH
- Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
- (2017) Elodie M Kuntz et al. NATURE MEDICINE
- CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients
- (2017) M Matsushita et al. Blood Cancer Journal
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
- (2017) Delphine Rea et al. HAEMATOLOGICA
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
- (2016) H Hjorth-Hansen et al. LEUKEMIA
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- (2016) M Ilander et al. LEUKEMIA
- Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients
- (2016) Vaclava Polivkova et al. PLoS One
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients
- (2016) Cesarina Giallongo et al. PLoS One
- WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
- (2015) Jason Brayer et al. AMERICAN JOURNAL OF HEMATOLOGY
- KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy
- (2015) D. T. Yeung et al. BLOOD
- New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT
- (2015) X Chang et al. BONE MARROW TRANSPLANTATION
- Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients
- (2015) Giovanni Caocci et al. EXPERIMENTAL HEMATOLOGY
- Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity
- (2015) C. Cimen Bozkus et al. JOURNAL OF IMMUNOLOGY
- Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
- (2015) A Burchert et al. LEUKEMIA
- Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
- (2015) A Ray et al. LEUKEMIA
- Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
- (2015) Cesarina Giallongo et al. Frontiers in Oncology
- The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?
- (2014) Joshua F. Zeidner et al. LEUKEMIA & LYMPHOMA
- Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients
- (2014) P.K. Estrada-González et al. LEUKEMIA RESEARCH
- Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
- (2014) Cesarina Giallongo et al. PLoS One
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
- (2013) T. P. Hughes et al. BLOOD
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target
- (2013) Yang Yang et al. CANCER LETTERS
- A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation
- (2013) Mohamed Shanavas et al. Clinical Lymphoma Myeloma & Leukemia
- Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients
- (2013) Giorgio La Nasa et al. EXPERIMENTAL HEMATOLOGY
- Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy
- (2013) Mette Ilander et al. LEUKEMIA & LYMPHOMA
- Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation
- (2013) Hua Jin et al. PLoS One
- Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
- (2012) M Talpaz et al. LEUKEMIA
- Clinical reagents of GM-CSF and IFN-α induce the generation of functional chronic myeloid leukemia dendritic cells in vitro
- (2011) Kaizhi Weng et al. CYTOTECHNOLOGY
- RestrictedTRBVrepertoire in CD4+and CD8+T‐cell subsets from CML patients
- (2011) Yangqiu Li et al. Hematology
- Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
- (2011) Anna Kreutzman et al. PLoS One
- WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
- (2010) Yusuke Oji et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
- (2010) F. Palandri et al. HAEMATOLOGICA
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone
- (2010) Franck E. Nicolini et al. LEUKEMIA RESEARCH
- Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells
- (2009) Sabine Mumprecht et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells
- (2009) Wei Ge et al. LEUKEMIA RESEARCH
- IFNα activates dormant haematopoietic stem cells in vivo
- (2009) Marieke A. G. Essers et al. NATURE
- Dasatinib suppresses in vitro natural killer cell cytotoxicity
- (2008) S. J. Blake et al. BLOOD
- Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib
- (2008) R. Weichsel et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started